This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mesoblast Selects Medidata’s Cloud-based Clinical Research Platform To Accelerate Cutting-edge Stem Cell Research

Stocks in this article: MDSO

Medidata Solutions (NASDAQ: MDSO) continues to lead the market with its cloud-based clinical development platform through a new customer commitment from Mesoblast Limited, a world leader in developing biologic products for the broad field of regenerative medicine. Mesoblast will implement Medidata Rave ®, including Rave Safety Gateway and Rave Targeted SDV, and Medidata Coder™ across its clinical studies to support the development of treatments based on its proprietary adult stem cell technology.

Medidata’s platform is seen as a cost-efficient solution to improve Mesoblast’s clinical trial efficiencies across multiple therapeutic areas, to effectively monitor and control risks, and to streamline trial execution to meet tight deadline goals.

Medidata Rave, a leading electronic data capture (EDC) and clinical data management (CDM) solution, enables real-time visibility into clinical trial data. The flexibility of Rave allows Mesoblast to proactively adjust a trial’s data validation plan and management processes, and also apply learnings to other studies in a timely fashion to improve trial quality and efficiency.

Mesoblast selected Rave for its superior user experience and comprehensive functionality. The context-sensitive, on-screen help minimizes the dependence on calling help desks and eliminates delays in entering and cleaning data. Moreover, research sites’ familiarity with Rave will help Mesoblast to expedite site initiation.

Further building out the clinical trial process, Mesoblast selected Rave Targeted SDV to reduce site monitoring costs through a risk-based approach. The implementation of Rave Safety Gateway and Medidata Coder will enable Mesoblast to increase the efficiency of its safety reporting process.

  • “Mesoblast chose Medidata Solutions for our ability to drive improved efficiency and more effective decision making across their trials process,” said Tarek Sherif, CEO, Medidata Solutions. “We’re very excited that the Medidata Clinical Cloud is playing a key role in allowing Mesoblast to execute at the forefront of regenerative medicine research and adult stem cell technology.”

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,075.60 +45.39 0.25%
S&P 500 2,090.75 +8.87 0.43%
NASDAQ 4,802.2350 +28.7630 0.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs